Investing

ArriVent BioPharma : AVBP

AVBP

Stock Data

$33.64

$0.05 (0.15%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating innovative medicines for cancer patients with critical needs. It specializes in developing targeted therapies, particularly for non-small-cell lung cancer (NSCLC) and other solid tumors. Among its key projects is Furmonertinib, a promising drug in phase 3 trials aimed at NSCLC. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma is also known for its strategic partnership with Aarvik Therapeutics Inc., enhancing its development capabilities.

All ArriVent BioPharma Articles

3 Articles

Lee Jackson | Dec 23, 2025 at 8:13 AM EST

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of…

Trey Thoelcke | Jun 16, 2024 at 8:45 AM EDT

Big Warren Buffett Purchase Highlights Recent Insider Buying

Warren Buffett has purchased more of his favorite energy stock. Other notable insider buying in the past week came from…

Trey Thoelcke | Feb 5, 2024 at 12:09 PM EST

Insider Buying at These Biotechs Is Huge

As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at…